（TSE：4548）
-
1Q of FY2025 Results P3-7
Overview
Domestic Pharmaceuticals
Overseas Pharmaceuticals
Bulk Products / CDMO, Royalty, LAL Business
-
Research and Development P8-13
SI-6603 (Lumbar disc herniation)
Gel-One (Osteoarthritis of the knee and the hip)
SI-722 (Interstitial cystitis and bladder pain syndrome)
SI-449 (Adhesion Barrier)
-
Appendix P14-17
FY2025 Forecasts
Basic Policy on Profit Distribution
Main products and Key Alliances with Companies in Japan and Overseas
(Including Products under Development)
2
Contents
E x p l o r i n g t h e I n n o v a t i v e P r o m i s e o f G l y c o s c i e n c e
E x p l o r i n g t h e I n n o v a t i v e
1Q of FY2025 Results
P r o m i s e o f G l y c o s c i e n c e
3
Net sales: Down 12.9% on a steep decline in royalty income, despite higher sales of domestic pharmaceuticals and overseas pharmaceuticals.
Income: Down sharply due to the decrease in royalty income.
Although 1Q income fell below the full-year forecast of consolidated financial results, no revision to the forecast because of slippage of shipments of overseas pharmaceuticals into 2Q and anticipated sales of investment securities.
Net Sales by Business Segment
Overseas Sales Ratio
（Millions of Yen）
1Q FY2024
Results
1Q FY2025
Results
% of
Change
-12.9%
Net Income
10,022
8,731
Operating Income
1,640
(365)
ー%
Ordinary Income
2,186
(132)
ー%
Net Income
1,901
(200)
ー%
Net Income per Share
¥34.84
(¥3.68)
ー
10,022
-12.9％
(Millions of Yen)
2,829
2,962
939
2,388
1,948
732
1,147
3,012
2,791
8,731
*excluding royalty income
56.2%
43.8%
FY2024 1Q
Other Performance Indicators
FY2024 1Q
FY2025 1Q
% of Change
FY2025 1Q
Domestic Overseas
R& D Expenses
（Millions of Yen）
Ratio of R& D expenses to sales
( excluding royalty income)
Ave. exchange rate during the period (US$1 ）
1,557 1,691 +8.6%
20.4％ 19.4％ -1.0Pt
¥155.9 ¥144.6 -¥11.3
FY2024 1Q FY2025 1Q
58.4% 41.6%
4
Overview for 1Q of FY2025
E x p l o r i n g t h e I n n o v a t i v e P r o m i s e o f G l y c o s c i e n c e
1Q of FY2025 Results
Domestic Pharmaceuticals
No major change in the market environment.
E x p l o r i n g t h e I n n o v a t i v e P r o m i s e o f G l y c o s c i e n c e
Net sales up 7.9% year on year on higher sales of ARTZ and the OPEGAN series attributable to shipment timing.
Sales Comparison
ARTZ（Joint-function improving agent）
ARTZ DispoOPEGAN seriesFY2024 1Q
FY2025 1Q
(Millions of Yen)
others
＋7.9％
2,791
3,012
11,600FY2025
Forecasts
Market environment:
・Number of patients increasing accompanying a rising elderly population.
However, flat or declining market for hyaluronic acid injectable treatments due to
factors including expansion of treatment options, such as topical preparations and
oral medications.
・Top share maintained. (approx. 80%*)
Maintaining trust by leveraging status as an original drug through appropriate
provision of information to medical institutions together with the sales partner.
Continuous holding of seminars at academic conferences.
Seikagaku sales: Up due to shipment timing.
OPEGAN series（Ophthalmic viscoelastic devices）
Market environment:
・Because of use mainly for cataract surgery, market expansion trend accompanying
growth in the elderly population.
・Top share maintained. (approx. 50%*)
Pursuit of further market penetration in cooperation with the sales partner.
*Source：Copyright © 2025 IQVIA. Calculated based on JPM April 2024 - June 2024, April 2025 - June 2025 by SKK , Reprinted with permission
Seikagaku sales: Up due to shipment timing.
5